Sakar Healthcare (SAKAR) Fundamentals 2026 — P/E 61.0x, Revenue Analysis | SniperIQ
Sakar Healthcare (SAKAR) is a India-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₹1,838 Crore, trading at ₹837.25 on the NSE. This SniperIQ fundamentals page covers Sakar Healthcare's valuation (P/E 61.0x, P/B 5.7x), profitability (net margin 12.1%), revenue (₹252 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Sakar Healthcare's market cap?
Sakar Healthcare (SAKAR) has a market capitalization of approximately ₹1,838 Crore, trading at ₹837.25 on the NSE. Market cap moves with the live share price.
What is Sakar Healthcare's P/E ratio?
Sakar Healthcare's trailing twelve-month P/E ratio is 61.0x, with a price-to-book (P/B) of 5.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Sakar Healthcare?
Sakar Healthcare runs a net profit margin of 12.1%, a gross margin of 31.5%, and an operating margin of 18.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Sakar Healthcare generate?
Sakar Healthcare reported revenue of ₹252 Crore for fiscal year 2026, with net income of ₹30 Crore and earnings per share (EPS) of 13.7. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Sakar Healthcare pay a dividend?
Sakar Healthcare does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Sakar Healthcare financially healthy?
Sakar Healthcare carries a debt-to-equity ratio of 0.17x and a current ratio of 1.28x, with a market beta of 0.38. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Sakar Healthcare a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Sakar Healthcare (SAKAR) the key facts are: market cap ₹1,838 Crore, P/E 61.0x, revenue ₹252 Crore, 52-week range 311-960. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Sakar Healthcare's full fundamentals live
Get Sakar Healthcare's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.